These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 20654753

  • 1. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM.
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [Abstract] [Full Text] [Related]

  • 2. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC.
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [Abstract] [Full Text] [Related]

  • 3. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact.
    Guido M, Romualdi D, Campagna G, Ricciardi L, Bompiani A, Lanzone A.
    Reprod Sci; 2010 Aug; 17(8):767-75. PubMed ID: 20595709
    [Abstract] [Full Text] [Related]

  • 4. Evidence that in healthy young women, a six-cycle treatment with oral contraceptive containing 30 mcg of ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass.
    Uras R, Orrù M, Etzi R, Peppi G, Marotto MF, Pilloni M, Zedda P, Lello S, Melis GB, Paoletti AM.
    Contraception; 2009 Feb; 79(2):117-21. PubMed ID: 19135568
    [Abstract] [Full Text] [Related]

  • 5. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial.
    Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A.
    Contraception; 2009 Feb; 79(2):111-6. PubMed ID: 19135567
    [Abstract] [Full Text] [Related]

  • 6. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 7. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 8. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO.
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [Abstract] [Full Text] [Related]

  • 9. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome.
    Gomes VA, Vieira CS, Jacob-Ferreira AL, Belo VA, Soares GM, França JB, Ferriani RA, Tanus-Santos JE.
    Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):211-6. PubMed ID: 22510229
    [Abstract] [Full Text] [Related]

  • 10. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).
    Podfigurna A, Meczekalski B, Petraglia F, Luisi S.
    J Endocrinol Invest; 2020 Apr; 43(4):483-492. PubMed ID: 31654312
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C, Hedon B, The HS, Höschen K, Binder N, Christoph A.
    Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
    [Abstract] [Full Text] [Related]

  • 12. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L, Dordoni D, Gastaldi C, Gastaldi A.
    Acta Eur Fertil; 1986 Jun; 17(1):19-25. PubMed ID: 2941960
    [Abstract] [Full Text] [Related]

  • 13. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR.
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
    Yildizhan R, Gokce AI, Yildizhan B, Cim N.
    Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
    [Abstract] [Full Text] [Related]

  • 15. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables.
    Winkler UH, Röhm P, Höschen K.
    Contraception; 2010 May; 81(5):391-400. PubMed ID: 20399945
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.
    Winkler UH, Sudik R.
    Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436
    [Abstract] [Full Text] [Related]

  • 18. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V, Di Sabatino A, Musacchio MC, Morgante G, Scolaro V, Cianci A, Petraglia F.
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [Abstract] [Full Text] [Related]

  • 19. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A, Cinar N, Bayraktar M, Yildiz BO.
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP, Hanjalic-Beck A.
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.